Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
Top Cited Papers
- 6 December 2007
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 14 (1) , 25-27
- https://doi.org/10.1038/nm1698
Abstract
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.Keywords
This publication has 15 references indexed in Scilit:
- Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzeesProceedings of the National Academy of Sciences, 2007
- Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 BindingJournal of Virology, 2006
- Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoproteinVirology, 2006
- Anti‐HCV therapies in chimeric scid‐Alb/uPA mice parallel outcomes in human clinical application†Hepatology, 2006
- Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33Hepatology, 2006
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005
- Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological FunctionsJournal of Virology, 2004
- CD81-Dependent Binding of Hepatitis C Virus E1E2 HeterodimersJournal of Virology, 2003
- Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein ComplexesThe Journal of Experimental Medicine, 2003
- A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.Proceedings of the National Academy of Sciences, 1996